Biomarin Pharmaceutical Inc (BMRN)vsRegeneron Pharmaceuticals Inc (REGN)
BMRN
Biomarin Pharmaceutical Inc
$56.77
+0.53%
HEALTHCARE · Cap: $10.81B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.11%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 360% more annual revenue ($14.92B vs $3.24B). REGN leads profitability with a 29.6% profit margin vs 8.3%. BMRN appears more attractively valued with a PEG of 0.69. REGN earns a higher WallStSmart Score of 64/100 (C+).
BMRN
Buy55
out of 100
Grade: C-
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.7%
Fair Value
$175.57
Current Price
$56.77
$118.80 discount
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
2.8% revenue growth
ROE of 4.3% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : BMRN
The strongest argument for BMRN centers on Altman Z-Score, Debt/Equity, PEG Ratio. PEG of 0.69 suggests the stock is reasonably priced for its growth.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : BMRN
The primary concerns for BMRN are Revenue Growth, Return on Equity, Piotroski F-Score. A P/E of 40.3x leaves little room for execution misses.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
BMRN profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.30 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (64/100 vs 55/100), backed by strong 29.6% margins and 19.0% revenue growth. BMRN offers better value entry with a 65.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biomarin Pharmaceutical Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BioMarin Pharmaceutical Inc. develops and markets therapies for people with rare diseases and serious and life-threatening medical conditions. The company is headquartered in San Rafael, California.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?